Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society

Kathryn A. Martin, R. Rox Anderson, R. Jeffrey Chang, David A. Ehrmann, Rogerio A. Lobo, Mohammad H Murad, Michel M. Pugeat, Robert L. Rosenfield

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Objective To update the Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline, published by the Endocrine Society in 2008. Participants The participants include an Endocrine Society-appointed task force of seven medical experts and a methodologist. Evidence This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation system to describe the strength of recommendations and the quality of evidence. The task force commissioned two systematic reviews and used the best available evidence from other published systematic reviews and individual studies. Consensus Process Group meetings, conference calls, and e-mail communications facilitated consensus development. Endocrine Society committees, members, and cosponsoring organizations reviewed and commented on preliminary drafts of the guidelines. Conclusion We suggest testing for elevated androgen levels in all women with an abnormal hirsutism score. We suggest against testing for elevated androgen levels in eumenorrheic women with unwanted local hair growth (i.e., in the absence of an abnormal hirsutism score). For most women with patient-important hirsutism despite cosmetic measures (shaving, plucking, waxing), we suggest starting with pharmacological therapy and adding direct hair removal methods (electrolysis, photoepilation) for those who desire additional cosmetic benefit. For women with mild hirsutism and no evidence of an endocrine disorder, we suggest either pharmacological therapy or direct hair removal methods. For pharmacological therapy, we suggest oral combined estrogen-progestin contraceptives for the majority of women, adding an antiandrogen after 6 months if the response is suboptimal. We recommend against antiandrogen monotherapy unless adequate contraception is used. We suggest against using insulin-lowering drugs. For most women who choose hair removal therapy, we suggest laser/photoepilation.

Original languageEnglish (US)
Pages (from-to)1233-1257
Number of pages25
JournalJournal of Clinical Endocrinology and Metabolism
Volume103
Issue number4
DOIs
StatePublished - Apr 1 2018

Fingerprint

Hirsutism
Androgen Antagonists
Androgens
Hair Removal
Teleconferencing
Cosmetics
Testing
Progestins
Contraceptive Agents
Electrolysis
Pharmacology
Advisory Committees
Estrogens
Therapeutics
Consensus
Insulin
Guidelines
Committee Membership
Lasers
Communication

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Martin, K. A., Rox Anderson, R., Jeffrey Chang, R., Ehrmann, D. A., Lobo, R. A., Murad, M. H., ... Rosenfield, R. L. (2018). Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society. Journal of Clinical Endocrinology and Metabolism, 103(4), 1233-1257. https://doi.org/10.1210/jc.2018-00241

Evaluation and Treatment of Hirsutism in Premenopausal Women : An Endocrine Society. / Martin, Kathryn A.; Rox Anderson, R.; Jeffrey Chang, R.; Ehrmann, David A.; Lobo, Rogerio A.; Murad, Mohammad H; Pugeat, Michel M.; Rosenfield, Robert L.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 103, No. 4, 01.04.2018, p. 1233-1257.

Research output: Contribution to journalArticle

Martin, KA, Rox Anderson, R, Jeffrey Chang, R, Ehrmann, DA, Lobo, RA, Murad, MH, Pugeat, MM & Rosenfield, RL 2018, 'Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society', Journal of Clinical Endocrinology and Metabolism, vol. 103, no. 4, pp. 1233-1257. https://doi.org/10.1210/jc.2018-00241
Martin, Kathryn A. ; Rox Anderson, R. ; Jeffrey Chang, R. ; Ehrmann, David A. ; Lobo, Rogerio A. ; Murad, Mohammad H ; Pugeat, Michel M. ; Rosenfield, Robert L. / Evaluation and Treatment of Hirsutism in Premenopausal Women : An Endocrine Society. In: Journal of Clinical Endocrinology and Metabolism. 2018 ; Vol. 103, No. 4. pp. 1233-1257.
@article{48fd69f7eaa74d57a5c0f09cceb930fd,
title = "Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society",
abstract = "Objective To update the Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline, published by the Endocrine Society in 2008. Participants The participants include an Endocrine Society-appointed task force of seven medical experts and a methodologist. Evidence This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation system to describe the strength of recommendations and the quality of evidence. The task force commissioned two systematic reviews and used the best available evidence from other published systematic reviews and individual studies. Consensus Process Group meetings, conference calls, and e-mail communications facilitated consensus development. Endocrine Society committees, members, and cosponsoring organizations reviewed and commented on preliminary drafts of the guidelines. Conclusion We suggest testing for elevated androgen levels in all women with an abnormal hirsutism score. We suggest against testing for elevated androgen levels in eumenorrheic women with unwanted local hair growth (i.e., in the absence of an abnormal hirsutism score). For most women with patient-important hirsutism despite cosmetic measures (shaving, plucking, waxing), we suggest starting with pharmacological therapy and adding direct hair removal methods (electrolysis, photoepilation) for those who desire additional cosmetic benefit. For women with mild hirsutism and no evidence of an endocrine disorder, we suggest either pharmacological therapy or direct hair removal methods. For pharmacological therapy, we suggest oral combined estrogen-progestin contraceptives for the majority of women, adding an antiandrogen after 6 months if the response is suboptimal. We recommend against antiandrogen monotherapy unless adequate contraception is used. We suggest against using insulin-lowering drugs. For most women who choose hair removal therapy, we suggest laser/photoepilation.",
author = "Martin, {Kathryn A.} and {Rox Anderson}, R. and {Jeffrey Chang}, R. and Ehrmann, {David A.} and Lobo, {Rogerio A.} and Murad, {Mohammad H} and Pugeat, {Michel M.} and Rosenfield, {Robert L.}",
year = "2018",
month = "4",
day = "1",
doi = "10.1210/jc.2018-00241",
language = "English (US)",
volume = "103",
pages = "1233--1257",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "4",

}

TY - JOUR

T1 - Evaluation and Treatment of Hirsutism in Premenopausal Women

T2 - An Endocrine Society

AU - Martin, Kathryn A.

AU - Rox Anderson, R.

AU - Jeffrey Chang, R.

AU - Ehrmann, David A.

AU - Lobo, Rogerio A.

AU - Murad, Mohammad H

AU - Pugeat, Michel M.

AU - Rosenfield, Robert L.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Objective To update the Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline, published by the Endocrine Society in 2008. Participants The participants include an Endocrine Society-appointed task force of seven medical experts and a methodologist. Evidence This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation system to describe the strength of recommendations and the quality of evidence. The task force commissioned two systematic reviews and used the best available evidence from other published systematic reviews and individual studies. Consensus Process Group meetings, conference calls, and e-mail communications facilitated consensus development. Endocrine Society committees, members, and cosponsoring organizations reviewed and commented on preliminary drafts of the guidelines. Conclusion We suggest testing for elevated androgen levels in all women with an abnormal hirsutism score. We suggest against testing for elevated androgen levels in eumenorrheic women with unwanted local hair growth (i.e., in the absence of an abnormal hirsutism score). For most women with patient-important hirsutism despite cosmetic measures (shaving, plucking, waxing), we suggest starting with pharmacological therapy and adding direct hair removal methods (electrolysis, photoepilation) for those who desire additional cosmetic benefit. For women with mild hirsutism and no evidence of an endocrine disorder, we suggest either pharmacological therapy or direct hair removal methods. For pharmacological therapy, we suggest oral combined estrogen-progestin contraceptives for the majority of women, adding an antiandrogen after 6 months if the response is suboptimal. We recommend against antiandrogen monotherapy unless adequate contraception is used. We suggest against using insulin-lowering drugs. For most women who choose hair removal therapy, we suggest laser/photoepilation.

AB - Objective To update the Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline, published by the Endocrine Society in 2008. Participants The participants include an Endocrine Society-appointed task force of seven medical experts and a methodologist. Evidence This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation system to describe the strength of recommendations and the quality of evidence. The task force commissioned two systematic reviews and used the best available evidence from other published systematic reviews and individual studies. Consensus Process Group meetings, conference calls, and e-mail communications facilitated consensus development. Endocrine Society committees, members, and cosponsoring organizations reviewed and commented on preliminary drafts of the guidelines. Conclusion We suggest testing for elevated androgen levels in all women with an abnormal hirsutism score. We suggest against testing for elevated androgen levels in eumenorrheic women with unwanted local hair growth (i.e., in the absence of an abnormal hirsutism score). For most women with patient-important hirsutism despite cosmetic measures (shaving, plucking, waxing), we suggest starting with pharmacological therapy and adding direct hair removal methods (electrolysis, photoepilation) for those who desire additional cosmetic benefit. For women with mild hirsutism and no evidence of an endocrine disorder, we suggest either pharmacological therapy or direct hair removal methods. For pharmacological therapy, we suggest oral combined estrogen-progestin contraceptives for the majority of women, adding an antiandrogen after 6 months if the response is suboptimal. We recommend against antiandrogen monotherapy unless adequate contraception is used. We suggest against using insulin-lowering drugs. For most women who choose hair removal therapy, we suggest laser/photoepilation.

UR - http://www.scopus.com/inward/record.url?scp=85045443695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045443695&partnerID=8YFLogxK

U2 - 10.1210/jc.2018-00241

DO - 10.1210/jc.2018-00241

M3 - Article

C2 - 29522147

AN - SCOPUS:85045443695

VL - 103

SP - 1233

EP - 1257

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 4

ER -